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neuroblastoma is an aggressive childhood cancer arising from sympatho-adrenergic neuronal 
progenitors. the low survival rates for high-risk disease point to an urgent need for novel targeted 
therapeutic approaches. Detailed molecular characterization of the neuroblastoma genomic landscape 
indicates that ALK-activating mutations are present in 10% of primary tumours. Together with other 
mutations causing RAS/MAPK pathway activation, ALK mutations are also enriched in relapsed 
cases and ALK activation was shown to accelerate MYCN-driven tumour formation through hitherto 
unknown ALK-driven target genes. to gain further insight into how ALK contributes to neuroblastoma 
aggressiveness, we searched for known oncogenes in our previously reported ALK-driven gene signature. 
We identified ETV5, a bona fide oncogene in prostate cancer, as robustly upregulated in neuroblastoma 
cells harbouring ALK mutations, and show high ETV5 levels downstream of the RAS/MAPK axis. 
Increased ETV5 expression significantly impacted migration, invasion and colony formation in vitro, 
and ETV5 knockdown reduced proliferation in a murine xenograft model. We also established a gene 
signature associated with ETV5 knockdown that correlates with poor patient survival. Taken together, 
our data highlight ETV5 as an intrinsic component of oncogenic ALK-driven signalling through the MApK 
axis and propose that ETV5 upregulation in neuroblastoma may contribute to tumour aggressiveness.
Neuroblastoma is the most common extracranial solid paediatric tumour, accounting for 15% of all childhood 
cancer deaths and arises from the developing sympathetic nervous system1. In patients with high-risk disease, 
5-year event-free survival is less than 50%2, with survivors often suffering from severe side-effects associated 
with current intensive multi-modal therapies and relapse after first-line therapy1. Recent sequencing efforts have 
established the mutational landscape of primary and relapsed neuroblastoma. Primary neuroblastomas, similar 
to other embryonic tumours, have a very low mutation burden. The ‘anaplastic lymphoma kinase’ (ALK) tyrosine 
kinase receptor is the only target with significant recurrent mutations occurring in up to 10% of sporadic cases 
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and a small fraction of germline mutations3–5. Of further interest, ALK mutations, together with other mutations 
affecting the RAS/MAPK pathway, appear to be further enriched in relapsed cases, either through selection of 
minor subclones present at diagnosis or mutations arising during therapy6. Recently, ALKAL1 and ALKAL2 were 
identified as potent ligands binding to the extracellular domain of ALK7. In addition to neuroblastoma, ALK acti-
vation also occurs in other tumour entities, most notably through activating fusion genes in non-small cell lung 
cancer (NSCLC) and anaplastic large cell lymphoma (ALCL)8.
We previously reported that combined occurrence of MYCN amplification and the ALKF1174L mutation in 
primary tumours resulted in a very aggressive tumour phenotype in patients3. Moreover, further in vivo ALKF1174L 
modelling showed drastic acceleration of MYCN-driven tumour formation in transgenic mice and zebrafish9,10. 
One possible mechanism through which ALK mutations may render neuroblastoma more aggressive is through 
increased MYCN activity resulting from PI3K-directed activation of ERK5 transcription levels or inhibiting 
GSK3ß-mediated repression of MYCN protein degradation11,12. Further, we recently identified a novel mutant 
ALK-controlled mechanism driving MYCN activity through PI3K/AKT-FOXO3a-controlled downregulation of 
HBP1, the latter being a negative regulator of MYCN13. IRS2 was also recently revealed as an important protein 
mediating survival through the PI3K/AKT-FOXO3 signalling axis14.
We previously showed that ALK signals both through the MAPK and PI3K/AKT pathways in neuroblastoma 
cells5. We now further explored our previously established 77-gene signature driven in neuroblastoma by consti-
tutive ALK signalling, after ALK inhibition, and identify ETV5 as induced by the ALK mutant protein5. ETV5 is 
a member of the polyomavirus enhancer activator 3 (PEA3) subfamily of the E26 transformation specific gene 
(ETS) transcription factors known to be part of the MAPK signalling pathway. We further investigated ETV5 in 
neuroblastoma models, given its established developmental role in neural crest cell lineage decisions and neu-
ronal progenitor cell proliferation15, to further explore the MAPK axis of ALK signalling. We confirm and further 
extend the findings by Lopez-Delisle et al. (2018), and functionally characterize the role of elevated ETV5 in the 
neuroblastoma phenotype in vitro and in vivo. We demonstrate that elevated ETV5 contributes to migration, clo-
nogenic potential and invasive properties of human neuroblastoma cells while ETV5 knockdown in a xenograft 
model attenuates proliferation and tumour growth. Finally, we established a gene signature associated with ETV5 
knockdown, which correlates with poor overall survival in patients with neuroblastoma.
Results
ETV5 is transcriptionally regulated by activating ALK mutations or receptor-ligand stimula-
tion. In follow-up to our initial study, which established a 77-gene signature driven by constitutive ALK sig-
nalling5, we performed a time series analysis of ETV5 expression levels upon pharmacological ALK inhibition 
using the same ALK-specific tool compound (TAE-68416,17) in neuroblastoma cell lines carrying the ALK hotspot 
mutations ALKR1275Q (CLB-GA) and ALKF1174L (SH-SY5Y), ALK amplification (ALKamp, NB-1) and wild-type 
ALK (ALKwt,SK-N-AS, which harbours the NRASQ61K mutation). ETV5 expression was significantly downreg-
ulated in ALK-activated cell lines, while no effect was observed in SK-N-AS (ALKwt, NRASQ61K) cells (Fig. 1a). 
Supplementary Fig. S1 shows the endogenous ALK expression levels18 and the killing curve of TAE-684. Similar 
results were obtained with the ALK inhibitor, crizotinib, in CLB-GA and NB-1 cells while this effect was atten-
uated in SH-SY5Y cells which express the ALKF1174L mutant protein. The latter is in keeping with the significant 
lower responsiveness of this mutation to crizotinib9 (Supplementary Fig. S1). The reduction in ETV5 mRNA 
levels was confirmed on protein level 6 h after exposure to TAE-684 (Fig. 1b).
In an orthogonal approach, we next tested the effect of enhanced ALK activation by exposure to the ALKAL1 
ligand on ETV5 levels in IMR-32 (ALKwt) cells. This caused the expected increased induction of ETV5 protein 
expression 0.5 h and 6 h after stimulation (Fig. 1c). After stimulation, upregulated p-ALK levels are rapidly attenu-
ated through dephosphorylation in keeping with previously established signalling kinetics7. Using artificial stim-
ulation of the ALK receptor with a monoclonal antibody Lopez-Delisle et al. also observed an increase in ETV5 
mRNA levels after 6 hours19. Therefore, our data are in agreement with the activation of ALK leading to induction 
of expression of ETV5, as clearly shown here at the protein level. The half-life of ETV5 protein after expression 
induction has not been studied thus far but our findings suggest that the protein is stable up to at least 6 h after the 
ALK receptor activity itself has been downregulated. We also tested the effect of combined pharmacological ALK 
inhibition of ALK ligand-stimulated cells which blocked ALK signalling and ETV5 upregulation. This further 
confirmed ALK-dependent ETV5 regulation (Fig. 1c).
Following these in vitro experiments, we assessed the effect of activated ALK on ETV5 expression in vivo. 
Xenograft tumours of SH-SY5Y (ALKF1174L) cells from TAE-684-treated mice showed likewise ETV5 mRNA 
downregulation (Supplementary Fig. S1). ETV5 expression was further also evaluated in concert with ALK muta-
tional status in two large independent primary neuroblastoma cohorts in the R2 database20 (NRC and GSE49711 
datasets). Here, ETV5 expression was significantly elevated in ALKmut neuroblastomas compared to tumours 
harbouring ALKwt or lacking ALK amplifications (Supplementary Fig. S1). This positive correlation thus further 
supports ALK-dependent ETV5 regulation. Taken together, both in vitro and in vivo data further support a role 
for ETV5 as a target regulated downstream of ALK.
ALK fusion genes upregulate ETV5 expression in ALcL and nScLc. Given the importance of acti-
vated ALK signalling and since ALK fusion genes also achieve enhanced signalling in ALCL and NSCLC, we 
investigated ALK-induced ETV5 expression in these cancer entities. We confirmed that in NPM-ALK-harbouring 
Karpas-299 cells (ALCL) and EML4-ALK-harbouring H3122 cells (NSCLC) ETV5 is downregulated upon treat-
ment with the ALK inhibitors, TAE-684 and crizotinib (Fig. 1d). In addition, expression of either ALK mutant 
proteins (ALKF1174L and ALKR1275Q) or ALK fusion proteins (NPM-ALK and EML4-ALK) in Il-3-dependent Ba/F3 
pro-B cells caused upregulation of ETV5 levels (Fig. 1e). Subsequent TAE-684 treatment of Ba/F3 cells depend-
ent on fusion or mutant ALK proteins also reversed ETV5 expression to the level of the parental Ba/F3 cells, 
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Figure 1. ALK regulates ETV5 expression through the MAPK signalling pathway. (a) Relative ETV5 mRNA 
expression levels in four different neuroblastoma cell lines treated for indicated time periods with a vehicle 
control (DMSO) or the ALK inhibitor, TAE-684 (0.3 µM). (nCLB-GA, SK-N-AS, SH-SY5Y = 4; nNB-1 = 5; mean with 
error bars representing 95% CI after error propagation with mean centring and scaling to control). (b) Western 
blot analysis for p-ALK, total ALK, ETV5, p-ERK1/2 and total ERK1/2 in four different neuroblastoma cell 
lines after ALK inhibition with TAE-684 (0.3 µM, 6 h). (cropped images, full-length images are presented in 
Supplementary Figs. S5–6). (c) Western blot analysis for p-ALK, total ALK, ETV5 and p-ERK1/2 in IMR-32 
after stimulation with ALK ligand (ALKAL1) for 30 min or 6 h and subsequent treatment with ALK inhibitor, 
crizotinib (0.25 µM). (cropped images, full-length images are presented in Supplementary Fig. S7a). (d) Relative 
ETV5 mRNA expression levels in non-neuroblastoma ALKoma tumour cell lines Karpas-299 (ALCL) and 
H3122 (NSCLC) after a 6 h treatment with a vehicle control (DMSO) or the ALK inhibitors, crizotinib (0.5 µM) 
or TAE-684 (0.3 µM). (n = 1; mean with error bars representing SD after error propagation). (e) Relative Etv5 
mRNA expression levels in ALK-dependent Ba/F3 cells 5 h post-treatment with a vehicle control (DMSO) or 
the ALK inhibitor, TAE-684 (0.3 µM). (n = 1; mean with error bars representing SD after error propagation). 
(f,g) Relative ETV5 mRNA expression levels in four different neuroblastoma cell lines after a 6 h treatment with 
a vehicle control (DMSO) or the MEK inhibitor, U-0126 (8 µM) and the PI3K inhibitor, pictilisib (500 nM). 
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indicating that the observed ETV5 upregulation is a direct consequence of activated ALK. In summary, our data 
indicate that ETV5 regulation by activated ALK is a conserved feature across different cancer and cell types.
ALK regulates ETV5 through the MAPK signalling pathway. To evaluate through which ALK 
downstream signalling axis ETV5 is regulated in neuroblastoma cells, we treated CLB-GA (ALKR1275Q), NB-1 
(ALKamp), SK-N-AS (ALKwt, NRASQ61K) and SH-SY5Y (ALKF1174L) cells with inhibitors for the two major path-
ways downstream of ALK. We used U-0126 as a MAPK inhibitor and pictilisib as a PI3K inhibitor5,21. Results 
reveal ETV5 downregulation only after blocking the MAPK pathway and not the PI3K/AKT pathway (Fig. 1f,g 
and Supplementary Fig. S1). In agreement with earlier reports, SH-SY5Y responds mildly to the MAPK inhibitor 
U-012622–24, whereas CLB-GA responds more strongly to the PI3K/AKT inhibitor pictilisib. This can be explained 
by compensation by the alternate pathway, since it is known that the RAS/MAPK and PI3K/AKT pathways com-
municate at many nodes25. Additionally, both the RET and ALK tyrosine kinase receptors are strongly active in the 
CLB-GA cell line, which both signal through both pathways (data not shown)5,26. Further, as expected, pERK1/2 
protein levels were reduced upon pharmacological ALK inhibition in CLB-GA (ALKR1275Q), NB-1 (ALKamp) and 
SH-SY5Y (ALKF1174L) cells, while levels were unaffected in SK-N-AS (ALKwt, NRASQ61K) cells (Fig. 1b). Moreover, 
IMR-32 (ALKwt) cells stimulated with the ALKAL1 ALK ligand also showed p-ERK1/2 upregulation in keeping 
with MAPK activation (Fig. 1c). Our findings indicate that ETV5 is regulated downstream of activated ALK 
through MAPK-signalling, in line with previous studies reporting ETV5 as a downstream target of RAS/MAPK 
signalling in other cellular contexts19,27,28.
In addition to ALK mutations, sequencing studies have also identified activating mutations in other genes 
upstream of MAPK signalling (including HRAS, NRAS, KRAS, NF1 and BRAF) in neuroblastomas22, particularly 
in relapsed cases. Therefore, we tested the effect of MAPK inhibition using the U-0126 MEK inhibitor in SK-N-AS 
(ALKwt, NRASQ61K) cells, in which the NRASQ61K mutation resulted in high pERK levels (Fig. 1b, Supplementary 
Table S1). We observed that SK-N-AS cells were highly sensitivity to MEK inhibition with concomitant strong 
downregulation of ETV5 expression (Fig. 1f)22. This finding demonstrates that elevated ETV5 levels can result 
from other upstream MAPK activating events than ALK mutation. To further analyse the relationship between 
ETV5 expression and MAPK activation, we investigated ETV5 expression levels in primary neuroblastomas in the 
GSE49711 dataset with and without RAS/MAPK pathway mutations (including ALK mutations29) (GSE120572). 
Tumours harbouring RAS/MAPK pathway mutations displayed significantly higher ETV5 expression. A sec-
ond analysis in this cohort separating neuroblastomas harbouring either mutant ALK (ALKmut) or mutations 
in other RAS/MAPK pathway genes (RAS/MAPK mutwithout ALK) also revealed significant differences compared 
to wild-type backgrounds (Fig. 1h). Next, we analysed the correlation between ETV5 levels and a RAS/MAPK 
activity score30 in a panel of 28 neuroblastoma cell lines and two independent cohorts of 283 and 498 primary 
neuroblastomas tumours (NRC and GSE49711 datasets, respectively), and found a significant positive correlation 
(p-values 0.0345, 1.147e-10 and 4.051e-9, respectively, Supplementary Fig. S1). Our findings thus point towards a 
MAPK pathway-dependent ALK-driven regulation of ETV5 in neuroblastoma. In line with our findings, Eleveld 
et al.31 recently established a 6-gene core RAS/MAPK pathway signature in neuroblastoma that includes ETV5. 
We also confirmed that the remaining genes, ETV1, ETV4, DUSP4 and DUSP6 display similar regulation as 
ETV5 upon the inhibition of MAPK, PI3K or ALK (Supplementary Fig. S2).
ETV5 is required for proliferation, migration and colony formation in neuroblastoma cells. To 
evaluate the functional impact of ETV5 levels in neuroblastoma cells with different mutant ALK backgrounds, 
we performed transient (siRNA) and stable (shRNA) ETV5 knockdown in CLB-GA (ALKR1275Q), NB-1 (ALKamp), 
SK-N-AS (ALKwt, NRASQ61K), and SH-SY5Y (ALKF1174L) cells. Migratory capacity was significantly reduced 
after transient ETV5 knockdown with either siETV5_63 or siETV5_65 in four different cell lines (Fig. 2a 
and Supplementary Fig. S3). ETV5 knockdown was confirmed on protein level (Fig. 2b). Further, phase con-
trast IncuCyte® imaging over 48 h of scratch wound closure illustrated this attenuation in migration (Fig. 2c 
and Supplementary Fig. S3, QR codes to access movie). In addition, ETV5 knockdown in SK-N-AS (ALKwt, 
NRASQ61K) and SH-SY5Y (ALKF1174L) cells dramatically impaired the ability of the cells to proliferate at limiting 
density and form colonies (Fig. 2d,e). In view of the previously reported role of ETV5 as a driver for invasion in 
several tumour types27, we also examined the impact of transient ETV5 knockdown on collagen type I substrate 
invasion. ETV5 knockdown in SK-N-AS (ALKwt, NRASQ61K) cells significantly reduced the invasive capacity of 
the cells (Supplementary Fig. S3).
The effect of ETV5 on tumour cell behaviour in vivo was analysed using the previously used SH-SY5Y xen-
ograft tumour model in immunocompromised mice32. These SH-SY5Y cells were transduced with shETV5 to 
achieve ETV5 knockdown in the xenograft tumours resulting from engraftment. The resulting ETV5 knockdown 
in vivo reduced tumour volume over time compared to tumours originating from the control SH-SY5Y cells 
(Fig. 3a). Histological examination of these tumours showed a reduction in proliferative activity as measured by 
Ki-67 staining (Fig. 3b,c). In vitro evaluation of the effect of ETV5 knockdown (shETV5) on the cell growth of 
SH-SY5Y cells showed a significant decrease in proliferative capacity as well (Supplementary Fig. S3). Caspase 
(nCLB-GA, NB-1, SH-SY5Y; U-0126 = 5; nSK-N-AS; U-0126 = 4; nCLB-GA, SK-N-AS, SH-SY5Y; pictilisib = 4; nNB-1, pictilisib = 6; mean with 
error bars representing 95% CI after error propagation with mean centring and scaling to control). (h) Boxplot 
representation of the log2 ETV5 mRNA expression levels in a large independent primary neuroblastoma 
cohort (GSE49711 dataset) with (left, 33 cases) and without RAS/MAPK pathway mutations (right, 226 cases) 
(GSE120572, left panel); and for cases with mutant ALK (ALKmut) or mutations in other RAS/MAPK pathway 
genes (Mutwithout ALK) (right panel). (*p < 0.05; **p < 0.01; ***p < 0.001).
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3 staining confirmed the exclusion of the involvement of apoptosis in the observed phenotypic effects (data not 
shown). ETV5 knockdown was confirmed on both RNA and protein levels (Fig. 3d,e). Taken together, our data 
indicate that ETV5 contributes to proliferation, migration, invasion and colony formation, which can, at least 
partly, explain the contribution to tumour aggressiveness.
the ETV5-driven transcriptional regulatory network is enriched for genes implicated in pro-
liferation and marks poor patient prognosis. To investigate the impact of the ETV5 transcription 
factor on the neuroblastoma cell transcriptome in relation to the observed phenotypic effects, we performed 
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Figure 2. ETV5 is required for cell migration and colony formation of neuroblastoma cells in vitro. (a) Wound 
confluence at 48 h after wound making on IncuCyte® of four different neuroblastoma cell lines after ETV5 
knockdown (siETV5_63 and siETV5_65) compared to control vector (siCtrl). (nCLB-GA, NB-1, SH-SY5Y = 3; nSK-
N-AS = 5; mean with error bars representing SD after error propagation). (b) Western blot analysis for ETV5 at 
48 h after ETV5 knockdown (siETV5_63 and siETV5_65) in four different neuroblastoma cell lines. (vertical 
line indicates cropped image, full-length images are presented in Supplementary Fig. S7b). (c) Phase contrast 
imaging of the scratch wound on IncuCyte® for CLB-GA at start (0 h) and after 48 h of ETV5 knockdown 
(siETV5_63 and siETV5_65) compared to control vector (siCtrl). Blue represents the initial scratch wound, 
yellow represents the scratch wound masking. (d,e) Colony formation analysis of two different NB cell lines 
after ETV5 knockdown with shETV5 compared to control vector (shCtrl SHC002; left panel) and after ETV5 
knockdown with siETV5_63 and siETV5_65 compared to control vector (siCtrl; middle and right panel). The 
upper panel shows the cristal violet staining, the lower panel shows the relative colony counts. (nshRNA = 2; 
nsiRNA, SK-N-AS = 4; nsiRNA, SH-SY5Y = 3; mean with error bars representing SD after error propagation) (*p < 0.05; 
**p < 0.01; ***p < 0.001).
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gene expression profiling after stable ETV5 knockdown in SH-SY5Y cells in vitro and in vivo after subcutane-
ous xenografting. An integrative analysis of these transcriptome datasets generated a total of 197 (112 up and 
85 down) significantly differentially expressed genes (Fig. 4a and Supplementary Fig. S4). Gene set enrichment 
analysis (GSEA)33 showed that Hallmark gene sets, “G2/M_CHECKPOINT”, “E2F_TARGETS” and “MYC_
TARGETS_V1”, are significantly enriched among genes downregulated after ETV5 knockdown, supporting the 
observed effect of ETV5 knockdown on proliferation (Fig. 4b). “APICAL_JUNCTION” (FDR = 0.102; nominal 
p-value = 0) and “MYOGENESIS” (FDR = 0.187; nominal p-value = 0) were among the top 12 Hallmark gene 
sets enriched in GSEA, in line with the migratory effects observed in vitro (Supplementary Fig. S4). Next, we 
determined an ETV5 activity score34 summarizing the expression of the 197 genes regulated by ETV5. When 
tested in two independent (transcriptome) datasets from primary neuroblastomas (NRC and GSE49711), the 
score correlated with worse overall and progression-free patient survival (Fig. 5 and Supplementary Fig. S4)35,36. 
In conclusion, given the enrichment of Hallmark gene sets involved in proliferation and migration, our ETV5 
driven transcriptome analysis supports the functional in vitro and in vivo observations.
Discussion
The ALK receptor tyrosine kinase plays an important role during normal neuronal development, and consti-
tutive ALK activation has been reported in up to 10% of all neuroblastoma cases37,38. Furthermore, activating 
ALK mutations have also been reported to be enriched in relapsed neuroblastoma together with other mutations 
driving RAS/MAPK signalling6,22. Activating ALK mutations combined with MYCN amplifications in neuro-
blastoma is associated with very poor prognosis in patients, which is mirrored by the finding that ALK mutation 
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Figure 3. ETV5 is required for cell growth of neuroblastoma cell lines in vivo. (a) In vivo observation of 
tumour growth of SH-SY5Y cells after ETV5 knockdown (shETV5) compared to control cells (shCtrl). 
(nshCtrl = 4; nshETV5 = 6; mean with error bars represent SD after error propagation). (b) Histological and 
immunohistochemical analysis of the xenograft tumour sections with H&E and Ki67 (proliferation) staining. 
(c) Relative Ki67 positive counts (%) for shETV5 xenograft tumours compared to control (shCtrl). (nshCtrl = 5; 
nshETV5 = 6; mean with error bars represent SD after error propagation). (d) Western blot analysis for ETV5 
after ETV5 knockdown (shETV5) in SH-SY5Y cells. (cropped images, full-length images are presented in 
Supplementary Fig. S7c). (e) Relative ETV5 mRNA expression levels of SH-SY5Y xenograft tumour samples 
after ETV5 knockdown (shETV5) compared to control (shCtrl). (nshCtrl = 4; nshETV5 = 5; mean with error bars 
representing SD after error propagation) (*p < 0.05; **p < 0.01; ***p < 0.001).
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accelerates tumour formation in animal models of MYCN-driven neuroblastoma5,10,12. In view of these findings, 
a more in-depth understanding of ALK signalling and how downstream target genes impact tumour biology 
and therapy resistance is of great importance and remained unresolved thus far. For this reason, we previously 
investigated the transcriptome downstream of ALK in neuroblastoma cells and defined a 77-gene signature5. 
Subsequently, we specifically sought ALK-upregulated genes implicated in normal neural crest and sympathetic 
nervous system development with putative oncogenic features and identified ETV5 as a strong candidate. Earlier 
reports established ETV5 as a downstream target of the RAS/MAPK pathway in neuroblastoma and other cell 
types19,27,28. We subsequently performed further experiments using pharmacological ALK inhibition and ALK 
ligand stimulation, and confirmed that ALK signalling regulates ETV5 expression levels regardless of whether 
wild-type or mutant ALK is expressed. By exposing neuroblastoma cells to MAPK and PI3K/AKT inhibitors, we 
confirmed that ALK signals through the MAPK pathway to control ETV5 levels. Further in line with our findings, 
ETV5 was reported to be part of the 6-gene core RAS/MAPK pathway signature specific for neuroblastoma31. We 
also confirm here that the other members of this core signature behave similarly to ETV5 upon treatment with the 
Figure 4. The ETV5 transcriptional regulatory network controls genes implicated in proliferation. (a) 
Hierarchical clustering and heat-map representation of common significant differentially expressed genes 
(112 up; 85 down) after in vitro and in vivo ETV5 knockdown in SH-SY5Y. (b) Gene Set Enrichment Analysis 
(GSEA) identifies the hallmark genesets “G2M_CHECKPOINT”, “E2F_TARGETS” and “MYC_TARGETS_V1” 
as significantly enriched among the downregulated genes after shETV5.
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different inhibitors. Strikingly, ETV5 levels in SK-N-AS (ALKwt, NRASQ61K) and IMR-32 (ALKwt) were strongly 
regulated by MAPK inhibition or ALK ligand stimulation, indicating that even in the wild-type ALK background, 
ETV5 expression plays an important role through MAPK pathway signalling and/or MAPK pathway activating 
mutations. Further, we extended these findings to other ALKomas, i.e. EML4-ALK-harbouring lung cancer and 
NPM-ALK-harbouring lymphomas.
After our extensive validation of ETV5 regulation by ALK and RAS/MAPK signalling in neuroblastoma cells, 
we investigated the contribution of ETV5 to the neuroblastoma cellular phenotype. ETV5 knockdown in vitro 
and in vivo impaired migration, invasion and proliferation of neuroblastoma cells. Our findings corroborate 
the findings of Hollenhorst et al.39 and Monge et al.40, who respectively demonstrated that ETV5 plays a role in 
prostate cancer cell migration and in the myometrial infiltration of Hec-1A endometrial cancer cells. ETV5 was 
shown to induce a more aggressive and infiltrative pattern of prostate cancer cells in the former study. ETS factors 
have also been linked to migration, proliferation and tumour formation in mammary tumours27,41. Likewise in 
bladder cancer, the expression of PEA3 family members were recently shown to be involved in malignant trans-
formation42. Our findings that ETV5 knockdown impaired neuroblastoma cell migration and invasive capacity 
are in line with these findings in multiple tumour entities. We further observed an effect of ETV5 on in vitro 
colony formation and in vivo proliferation in neuroblastoma cells, correspondingly as reported by Di Martino 
et al.42 in bladder cancer. A decrease in ability to form a compact colony is typical for Etv4/5 double knockout 
as well as undifferentiated embryonic cells43. Expression of this group of ETS transcription factors has also been 
correlated to expression of certain matrix metalloproteinases (MMP), amongst other molecules, which are known 
to degrade extra-cellular matrix components41. The precise molecular principle by which ETV5 impairs neuro-
blastoma cell migration and invasion remains, however, to be elucidated.
Our finding that ETV5 affects neuroblastoma cell migration, invasive and colony formation capacity and 
ETV5 upregulation through MAPK signalling (either through activated ALK or RAS pathway activation) sug-
gests that ETV5 may contribute to increased aggressiveness and relapse of neuroblastoma through darwinistic 
selection of ALK/RAS/MAPK pathway activating mutations during therapy. This is further in keeping with the 
ETV5-driven gene signature established in this study which also correlated with poor survival in patients with 
neuroblastoma. Additional studies, including orthotopic in vivo modelling, are however needed to further inves-
tigate and clarify the possible contribution of ETV5 to aggressive tumour cell behaviour. In this context, it is of 
interest that ETV5, together with ETV4, has been implicated in stemness of embryonic stem cells by promoting 
their naïve status43, as well as the terminal differentiation and neurite branching of dorsal root ganglion sensory 
neurons44 and, via induction by the BDNF/TrkB pathway, in neuronal outgrowth45. In embryonic stem cells, 
ETV5 has been proposed to be part of a large gene regulatory network of transcription factors in which OCT3/4 
and NANOG act as master regulators43.
Drug resistance remains a major challenge in the era of precision cancer treatment. The finding by Umapathy 
et al. that ALK-activated neuroblastoma cells are resistant to the MEK inhibitor, trametinib, due to PI3K/
AKT-driven feed-back response is of interest46 with regards to the known crosstalk between the MAPK and 
PI3K/AKT pathways. Together with our findings, this work further illustrates the importance of in-depth knowl-
edge of context-dependent signalling in oncogene-activated pathways and how they respond through rewiring 
upon drug targeting. At present, we can only speculate on a potential role for ETV5 in trametinib resistance in 
ALK-activated neuroblastoma. ETV5 levels were concomitantly downregulated in SK-N-AS cells in the course 
of their strong response to MEK inhibition in our experiments. These neuroblastoma cells harbour the activating 
NRASQ61K mutation in a wild-type ALK cellular background. In ALK-activating neuroblastoma cellular back-
grounds, the effects of ETV5 reduction on MEK inhibition were significant, albeit attenuated when compared to 
the same cell lines treated with ALK inhibitor. The negative MAPK regulator DUSP6 is previously shown to be 
regulated by ETV5 in zebrafish47, which could explain our previous finding of a MAPK negative feed-back loop in 
ALK-activated neuroblastoma cells5. As mentioned earlier, other members of the RAS/MAPK pathway signature 
in neuroblastoma31 behaved similarly to ETV5, albeit less pronounced, upon treatment with the different inhibi-
tors. These data thus suggest that ETV5 could be an important driver of this negative feed-back loop.
Figure 5. The ETV5 transcriptional regulatory network marks poor prognosis. ETV5 activity score, 
summarizing the expression of 197 genes regulated by ETV5, is correlated with worse overall (left panel) and 
progression-free patient survival (right panel) in the NRC dataset.
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ETV5 and other PEA3 family members, as well as several other ETS factors, are widely implicated in vari-
ous cancer entities such as prostate, Ewing and melanoma tumours27,48. Neuroblastomas and most likely other 
ALKomas can now be added to this growing list. Our finding implicating ETV5 in neuroblastoma cell migra-
tion, proliferation and invasion is in agreement with ETV5 overexpression causing enhanced proliferation and 
invasion in immortalized, non-transformed prostate epithelial cells48–50 and ETV5 functional inhibition attenu-
ating proliferation in mouse mammary cancer27. The broad implication of these transcription factors in cancer, 
creates a growing need for ETS transcription factor targeted therapy. In order to abolish ETV5 activity, possible 
approaches include emerging methods to target protein degradation51, interference with functional binding part-
ners and drugging key target genes or upstream activators such as MAPK signalling. Recent discoveries in the 
development of small molecules targeting ETS proteins raise hope52. Therefore, focussing on targeting ETV5 
activity could serve as a basis for new complementary or synergistic therapies oriented to targeting effectors 
downstream of ALK.
Materials and Methods
cell lines and inhibitors. Cell lines used, with their respective mutations, are listed in Supplementary 
Table S1. The murine interleukin 3 (Il-3)-dependent pro-B-Cell line, Ba/F3, was used as a model to obtain ALK-
dependent cells, owing to its potent growth capacity and use of kinase oncogene signalling53. Cells were grown in 
RPMI 1640 (Invitrogen) supplemented with 10% FCS, 100IU/ml penicillin/streptomycin, 2 mM L-glutamine and 
25 mM HEPES (Life Technologies). Ba/F3 cells were cultured in the presence of 1 ng/mL Il-3 (213-13, Peprotech). 
Cells were cultured at 37 °C in a 5% CO2/95% O2 humidified environment. Mycoplasma testing (Lonza) and short 
tandem repeat genotyping were regularly performed.
Cells were treated for indicated time periods with inhibitory compounds: the ALK inhibitors, NVP-TAE-684 
(0.32 µM, S1108, Novartis/SelleckChem), crizotinib (0.5 µM, PF-02341066, S1068, Pfizer/SelleckChem) or 
LDK-378 (0.2 µM, S7083, SelleckChem); the MEK inhibitors, U-0126 (8 µM, Sigma-Aldrich) or trametinib 
(0.05 µM, GSK1120212, S2673, SelleckChem); the dual PI3K/mTOR inhibitor, NVP-BEZ-235 (0.5 µM, S1009_3, 
SelleckChem) or the PI3K inhibitor pictilisib (0.5 µM, S1065, SelleckChem). Dimethyl sulfoxide (DMSO, VWR) 
was used to dissolve the compounds and served as vehicle control.
ALK constructs, siETV5 transfections/nucleofections and shETV5 transductions. Expression 
constructs for the F1174L and R1275Q ALK mutant proteins were generated as described in De Brouwer et al.3.
ETV5 knockdown used siRNA oligonucleotides from ON-TARGET plus SMARTpools (L-062952-01-0005, 
Dharmacon, referred to as siETV5) and LipofectamineTM RNAiMAX transfection Silencer® Select reagents 
(4392420-s4863 and –s4865, Fisher Scientific, referred to as siETV5_63 and siETV5_65 respectively). As a con-
trol, siCONTROL non-targeting (siCtrl) siRNA pool (D-001810-10-05, Dharmacon) and Negative Control #1 
siRNA (1299001, Fisher Scientific) were used. CLB-GA, NB-1 and SK-N-AS cells were transfected according to 
manufacturer’s instructions. SH-SY5Y cells were nucleofected with 100 nM of the above described siRNAs using 
the Neon Transfection System (Thermo Fisher Scientific).
Five ETV5 mission shRNAs were obtained from the TRC1 library (Sigma-Aldrich, TRCN0000013938 till 
−42). TRCN0000013938 (referred to as shETV5), was used throughout this manuscript as the optimal shRNA 
(target sequence: CCGGCCGTGACACTTAGTACATTAACTCGAGTTAATGTACTAAGTGTCACGGTTTTT). 
Lentiviral production was according to the Thermo Scientific Trans-Lentiviral Packaging Kit 
(TLP5913). Transduced SH-SY5Y and SK-N-AS cells were selected using 0.5–1 µg/ml puromy-
cin (P8833, Sigma-Aldrich). The transduction efficiency was determined by qPCR and west-
ern blotting. pLKO.1-puro Non-Mammalian shRNA control plasmid (SHC002, target sequence: 
CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTT, Sigma-Aldrich) 
was used as a negative control.
ALKAL1 ligand for ALK stimulation. The ALKAL1 ALK ligand was used to stimulate ALK signalling in 
cell culture by treatment with conditioned medium as previously described by Guan et al.7.
Reverse-Transcriptase quantitative Polymerase Chain Reaction (RT-qPCR). RT-qPCR was per-
formed on samples as previously described5. Expression levels of target genes were normalized to a minimum 
of three internal reference genes. All primer sequences were acquired by the use of RTPrimerDB (http://www.
rtprimerdb.org) (Supplementary Table S2)54. Expression analysis and error propagation was done using qBase-
PLUS software 1.5 (http://www.biogazelle.com)55. Error bars in figures represent SD or 95% CI after error prop-
agation with mean centring and scaling to control. For statistical testing, a paired two-tailed Student’s t-test was 
performed at the 5% significance level.
protein analysis. Protein isolation and western blotting was performed as previously described5. The fol-
lowing primary antibodies were used: anti-pY1604-ALK (1:500, 3341), anti-ALK (1:750, 3333), anti-pERK1/2 
(1:500, 9101S) and anti-ERK1/2 (1:500, 9102), all from Cell Signaling; anti-ETV5 from Abnova (1:500, 
H00002115-M01). For the loading control, anti-β-actin (Cell Signaling), anti-vinculin (Sigma Aldrich) and 
anti-GAPDH (Genetex) antibodies were used. Secondary antibodies were used from Cell Signaling. Imaging was 
done using the Amersham Imager 680 (GE Healthcare).
cell migration assays. Neuroblastoma cells were seeded for IncuCyte® scratch wound assay, while protein 
samples were simultaneously harvested from equivalent cell aliquots. Cells were seeded in an Imagelock 96-well 
plate (4379, Essen Bioscience). Uniform wounds were made in the confluent cell monolayer using the Incucyte® 
Wound Maker, and cells were re-transfected according to manufacturer’s instructions. Phase contrast imaging 
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took place every 2 h for a total of 48 h. Images were analysed using IncuCyte® S3TM 2018B-2019A software. Error 
bars in figures represent SD after error propagation with mean centring and scaling to control. For statistical test-
ing, a Levine’s test was performed in SPSS at the 1% significance level upon which an independent paired t-test 
was performed at the 5% significance level56,57.
colony formation assay. SK-N-AS cells were seeded at a concentration of 2000 cells per 6 cm dish, 
5000 SH-SY5Y cells were seeded per well of a 6-well plate. Cells were seeded in 2 or 3-fold for experiments. 
Subsequently colonies were allowed to form followed by fixation as previously described13. OpenCFU was used 
to quantify differences in colony forming capacity. Error bars in figures represent SD after error propagation. For 
statistical testing, a paired two-tailed Student’s t-test was performed at the 5% significance level.
collagen invasion assay. The collagen invasion assay of SK-N-AS cells after siETV5 transfection was per-
formed as previously described by De Wever et al.58. Error bars in figures represent SD after error propagation. 
For statistical testing, a Chi² test was performed at the 5% significance level.
cell proliferation assays. SH-SY5Y were transduced with shETV5 lentiviral particles as described above. 
Upon 6 days of puromycin selection, cells were seeded for IncuCyte® proliferation assay, while samples for pro-
tein and RNA were harvested simultaneously from equivalent cell aliquots. Cells were seeded in triplicate in a 
96-well plate (3596, Corning). Phase contrast imaging took place every 2 h for a total of 112 h. Images were ana-
lysed using the IncuCyte® ZoomTM 2016B software. Error bars in figures represent SD after error propagation. For 
statistical testing, a paired two-tailed Student’s t-test was performed at the 5% significance level.
Xenograft experiments. Animal experiments were performed according to the Guide for the Care and Use 
of Laboratory Animals (Eight Edition) following approval of the Committee on Ethics in Animal Experiments of 
Ghent University (Permit number: ECD 12/22)59. Persons who carried out the described experiments received 
appropriate training in animal care and handling. Mice were allowed to acclimatize before experiments began and 
were randomly assigned into two groups.
6 × 106 control SH-SY5Y or SH-SY5Y shETV5 cells were mixed with Matrigel® (354230, Corning) and subse-
quently injected subcutaneously into the left flank of female Crl:NU-Foxn1nu mice. Tumour growth was followed 
for 33 days. Tumour volume was assessed using a Caliper and calculated according to the spheroid formula: 
V = 0.5*a²*b with a being the smallest and b being the largest superficial diameter. Body weight and physical 
status of the animals were recorded daily until they were judged to be in discomfort by animal caretakers or max-
imum tumour volume was reached (2000 mm³) where after the animal was euthanized by cervical dislocation.
ETV5 mRNA levels were further evaluated upon treatment with TAE-684 of mice subcutaneously xenografted 
with SH-SY5Y as described by Heukamp et al.60.
immunohistochemistry. Xenograft tumours were fixed overnight in 4% paraformaldehyde, before dehy-
drating and embedding in paraffin. 5 µm sections were stained with H&E (Sigma). Antigen retrieval was carried 
out in citrate buffer (S236984, Dako) and endogenous peroxidases were blocked with 3% H2O2 in methanol 
(0390D, Fisher Chemical). Sections were incubated with anti-Ki67 (ab15580, Abcam) primary antibody and 
stained with biotin-conjugated secondary antibody followed by streptavidin-HRP-based DAB substrate devel-
opment (K3468, Dako). Images were acquired with the 40x objective on a Leica DM2000 LED microscope and 
processed with the LAS-X software. Images were evaluated by Fiji (ImageJ). Error bars of figures represent SD 
after error propagation. For statistical testing, a paired two-tailed Student’s t-test was performed at the 5% signif-
icance level.
Differential gene expression analysis by RNA sequencing. RNA sequencing was carried out on 
biological triplicates for shETV5-based knockdown experiments and on matched samples of subsequently 
generated mice xenograft tumours. Libraries for mRNA sequencing were prepared using the TruSeq stranded 
mRNA sample prep kit (Illumina), involving polyA-selection, fragmentation, adapter ligation, reverse transcrip-
tion and PCR amplification. Libraries were quantified on a Qubit 2.0 Fluorometer prior to paired-end sequenc-
ing with 75 bp read length on a NextSeq. 500 sequencer (Illumina). On average 24.7 M high-quality reads were 
generated per sample, with a minimal read count of 20.0 M reads per sample. For each sample, gene-level read 
counts were generated using Sailfish61. Counts were normalized using the TMM method (R-package edgeR), 
followed by Voom transformation and differential expression analysis with limma (R-package limma). Gene Set 
Enrichment Analysis (GSEA)33 was performed on the list ordered according to the differential expression statistic 
value (t) using the version 5.0 Hallmarks geneset catalogue. RNA sequencing data is available at ArrayExpress 
(E-MTAB-6713).
Signature score analysis in primary neuroblastomas. Two expression datasets were reanalysed, a 
partly published NRC dataset containing mRNA expression data (Affymetrix Exon arrays) from 283 neuroblas-
toma samples35,62,63 and the GSE49711 dataset including RNA sequencing data from 498 neuroblastomas that 
includes a subset of 259 neuroblastomas with defined RAS/MAPK mutation status (GSE120572)29,36,64. The RAS/
MAPK signature was retrieved from the Loboda et al. study30.
Signature score analysis was performed on these expression data using a rank-scoring algorithm as described 
by Fredlund et al.34. Correlation with survival was tested using Kaplan-Meier plots and log-rank analysis by 
grouping samples into 2 equal groups (scores above or below the median value) (R-survival package).
Statistical analysis. The statistical analysis performed are conform to each specific assay. Therefore it was 
chosen to describe the specific statistical analysis at the end of each assay description mentioned above.
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